课题基金 / 基金详情

CYSTINE-RICH GROWTH FACTOR FOR A TUMORIGENIC CELL LINE

CYSTINE-RICH GROWTH FACTOR FOR A TUMORIGENIC CELL LINE
富含胱氨酸的致瘤细胞系生长因子
批准号:
2099135
负责人:
Ginette Serrero
金额:
$6.73万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-04 至 1995-08-15

项目摘要

项目成果

Ginette Serrero的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mouse C3H teratoma-derived adipogenic cell line 1246 which grows and undergoes adipose differentiation in defined medium strictly requires insulin for both processes. Several variant insulin-independent cell lines were isolated. They have lost their ability to differentiate, have become tumorigenic and produce in their culture medium growth promoting and adipose differentiation inhibitory activities. Based on these results, it was suggested that the factors produced by the producer cells acted in an autocrine fashion and accounted for the change of phenotype observed in the insulin-independent variant. Moreover, it was assumed that growth factor production was responsible for the lesser growth factor requirement of tumorigenic insulin-independent cell lines. In order to examine these possibilities, we have isolated a highly tumorigenic insulin-independent cell line called PC. It was found that the highly tumorigenic PC cell line becomes dependent for its proliferation on a growth promoting activity found in its own culture medium. The growth factor called PCDGF was purified to homogeneity by a three chromatography step from the conditioned medium of PC cells. The pure factor is a 90 kDa glycoprotein. PCDGF was partially sequenced and shown to belong to a novel class of double cysteine rich proteins of unknown biological activity. Since it is the first characterization of a biological role for this novel class of protein and since the factor is produced by a highly tumorigenic cell line, it is proposed to further characterize the role, mechanism of action and structure of this growth factor at the cellular, biochemical and molecular levels. Experiments are proposed: to clone cDNA for the PC derived growth factor; to investigate the level of its expression in cell lines presenting increasing degree of tumorigenic properties and in normal and neoplastic tissues; to determine the phenotype of cells transfected with PCDGF cDNA in the sense and anti sense orientation; and to investigate its biological activity in vitro and its role in the in vivo tumorigenicity of cells expressing PCDGF. These studies will enable us to investigate in detail the biology of a novel growth factor and also to further our understanding in the role of autocrine mechanism in acquisition of tumorigenicity and loss of differentiation properties of mesodermal derived cell lines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
  • 批准号:
    10252075
  • 项目类别:
  • 资助金额:
    $82.69万
  • 财政年份:
    2018
  • 负责人:
    Ginette Serrero
  • 依托单位:
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
  • 批准号:
    10245772
  • 项目类别:
  • 资助金额:
    $106.21万
  • 财政年份:
    2018
  • 负责人:
    Ginette Serrero
  • 依托单位:
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
  • 批准号:
    9768982
  • 项目类别:
  • 资助金额:
    $14.17万
  • 财政年份:
    2017
  • 负责人:
    Ginette Serrero
  • 依托单位:
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
  • 批准号:
    10477924
  • 项目类别:
  • 资助金额:
    $7.08万
  • 财政年份:
    2017
  • 负责人:
    Ginette Serrero
  • 依托单位:
海外基金